MargaretMaryShowelMD

Oncology • Washington, DC

Instructor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Showel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Showel's full profile

Already have an account?

Office
5255 Loughboro Road NW
Johns Hopkins Kimmel Cancer Center
Washington, DC 20016
Phone+1 202-660-6500

Fax+1 202-660-6501

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
Rush University Medical CenterResidency, Internal Medicine, 2002 - 2006
Rush Medical College of Rush University Medical CenterClass of 2002

Certifications & Licensure

IL State Medical License 2005 - 2026
MD State Medical License 2006 - 2023
DC State Medical License 2017 - 2022

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS Start of enrollment: 2013 Jun 01
Completed
Phase 2

Publications & Presentations

PubMed

236 citations
Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Shannon R. McCurdy, Jennifer A. Kanakry, Margaret M. Showel, Hua Ling Tsai, Javier Bolaños-Meade
Blood. 2015-05-07
57 citations
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplan...
Shannon R. McCurdy, Christopher G. Kanakry, Hua Ling Tsai, Yvette L. Kasamon, Margaret M. Showel
Biology of Blood and Marrow Transplantation. 2018-02-01
93 citations
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Judith E. Karp, Brian M. Thomas, Jacqueline Greer, Christopher Sorge, Steven D. Gore
Clinical Cancer Research. 2012-12-15

Abstracts/Posters

Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
Margaret M. Showel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/margaret-showel